Prepared for
Diagnostics
Hero Finding
Clinical urgency starts the journey, but financial justification is the catalyst that actually moves it forward, cited as the top advancement trigger ahead of clinical need recognition and governance milestones.
Turnaround-time pressure and growing test volume trigger the buying conversation, with high-acuity clinical applications driving a meaningful share of in-house adoption decisions. But urgency alone does not advance the process. Financial justification is the single most cited catalyst that actually moves the decision forward, ahead of clinical need recognition and governance milestones. Cost is the most cited stakeholder objection, and the vast majority of buying processes take six months or more.
Top
Catalyst that advances the decision: financial justification
6+ mo
Of purchase processes take six months or more (vast majority)
Top
Stakeholder objection: cost (majority of reported pushback)
Top
Buying trigger: turnaround-time pressure (majority)
Study Design
N=65 clinical lab decision-makers across multiple tiers and testing delivery models · AI-moderated mixed-method interviews · 30+ minutes.
The sample was structured to capture the full clinical lab buyer population: lab directors and pathologists who initiate and champion purchases, hospital administrators who govern capital approval, and the committees that gate the final decision. Recruiting prioritized participants in an active buying journey across recent purchasers, active evaluators, and early consideration.
Sample segmentation
Mid-market tier · 30
Smaller tier · 25
Large tier · 10
Interview guide · core topics
- Need recognition: clinical pressures, volume triggers, and operational pain points that initiate the buying conversation
- Information gathering: peer networks, vendor interactions, conference channels, and emerging AI tool use
- Decision and approval: governance structure, committee composition, financial justification standards, and capital purchase guidelines
- Stakeholder mapping: who initiates, who champions, who pushes back, and when each role enters the journey
- Value frameworks: how labs define value across financial return, operational efficiency, and patient care
- Barriers and obstacles: cost, reimbursement, staffing, and approval process friction by segment
- Testing delivery model dynamics: in-house vs. send-out vs. hybrid behavior across the journey
- Tier segmentation: how the journey shifts across large, mid-market, and smaller institutions
Recruit criteria
- Lab director, pathologist, hospital administrator, or equivalent clinical diagnostics decision-maker with at least 2 years in current role
- Active role in capital-instrument purchasing as final decision-maker, committee member, evaluator, or influencer
- Clinical diagnostics laboratory performing patient-level diagnostic testing; translational labs excluded
- At least familiar with the relevant instrument category; has personally reviewed or written proposals for capital diagnostic instruments or assays
- In an active buying journey: recent purchase within 2 years, actively evaluating, in active procurement, or in early consideration
Key Findings
What the research surfaced about how clinical labs actually buy.
Six signals defined the journey map and the commercial engagement priorities by phase, segment, and stakeholder.
Top trigger
That opens the buying conversation: turnaround-time pressure
#1
Information source: peer recommendations
Majority
Of labs plan to expand in-house testing within 2 years
Vast majority
Of buying processes take 6+ months from need recognition to decision
Majority
Of stakeholder pushback centers on cost objections
Majority
Of capital-instrument purchases are initiated by the lab director
01
Clinical urgency opens the conversation, but financial feasibility is the gatekeeper that decides whether evaluation begins.
Turnaround-time pressure from clinicians and growing test volume are the top triggers, with high-acuity clinical applications driving a meaningful share of in-house adoption decisions. Urgency creates the conversation, but financial feasibility acts as an immediate gatekeeper: a small but meaningful minority of institutions cite it as a precondition before formal evaluation can even begin. The conversation moves forward only when the cost-per-test calculation pencils out against current send-out spend.
02
Buyer psychology skews cautious: only roughly one in five clinical labs are early adopters.
The technology adoption profile is risk-averse: roughly one in five labs are Early Adopters; the rest split between Fast Followers, Deliberate/Methodical, and Conservative segments. Fast followers wait for peer validation as their explicit lever. Deliberate/methodical buyers require evidence, clinical validation, and proven ROI. Operational anxieties reinforce caution: a majority cite staffing gaps and roughly half cite reimbursement uncertainty as top diagnostic testing challenges.
03
A majority of clinical labs plan to expand in-house testing within two years, but the conversion is gated by specific, addressable barriers.
Among labs likely to expand, financial viability and reimbursement, staffing and expertise constraints, insufficient testing volume to justify investment, and technology infrastructure gaps are the explicit barriers. Send-out labs face a fundamentally different objection surface than in-house labs: implementation-risk concerns appear at majority levels for send-out and near-zero for in-house, and send-out respondents report essentially no information sufficiency from vendors compared to a strong majority of in-house respondents.
04
Buyers follow a peer-first information journey: peer recommendations and site visits outweigh every vendor-generated source.
Peer recommendations from colleagues at other institutions are the #1 information source, followed by vendor sales reps, published clinical studies, professional conferences, and vendor websites. Peer site visits and reference customer interactions consistently deliver the most trusted evaluation experience. Vendor demos are valued when they address workflow integration, IT/EHR connectivity, and reimbursement pathways, but are viewed skeptically when they present staged demonstrations that avoid the hard operational questions.
05
Lab directors initiate the majority of purchases and champion a substantial share, but success requires a coalition that includes pathologists, clinicians, and finance.
Lab directors are the dominant initiators and earliest-stage participants, involved from the very beginning in a strong majority of cases. Pathologists provide technical validation and are more central at high-complexity large-tier institutions (versus mid-tier). Clinical specialists carry significant influence once involved, particularly at integrated-system-affiliated sites (versus standalone). Finance leadership holds effective veto power as the final approval gatekeeper, with non-academic institutions citing CFO involvement at materially higher rates than academic peers.
06
Staffing is the persistent pain point that threads through every phase of the journey.
Staffing appears in the top tier of issues at every phase: a majority cite staffing gaps as the top diagnostic challenge, a meaningful share cite lack of qualified staff as a top-three purchase barrier, a meaningful minority of stakeholder pushback centers on operational readiness concerns, and a sizeable share of expansion-planning labs cite staffing constraints as a barrier. Non-academic hospitals cite staffing gaps significantly more than academic peers, and rural labs report shortages at materially higher rates than urban.
“From a finance perspective, the cost would have to be offset by revenue being brought in by bringing these types of testing in-house. Without that case, the proposal does not advance.”— Hospital Administrator, Mid-Sized Non-Academic Hospital
Crosstab · Journey by Testing Delivery Model
In-house and send-out labs experience fundamentally different journeys: send-out labs face an implementation-risk and information-sufficiency gap that in-house labs do not.
Selected metrics by testing delivery model. The gaps define how commercial engagement should differ for labs evaluating an in-house transition versus those expanding existing in-house capacity.
| In-house labs | Send-out labs | |
|---|---|---|
| Define value primarily through financial return | Minority | Vast majority |
| Cite implementation risk as a stakeholder objection | Near zero | Majority |
| Report information sufficiency from vendors | Strong majority | Near zero |
| Cite ROI/business case as a stakeholder objection | Small minority | Meaningful share |
| Cite independent validation data gaps | Near zero | Meaningful share |
| Cite internal capital competition as objection | ~½ | Small minority |
| Cite staffing as primary capacity constraint | Strong majority | Minority |
N=65 clinical lab decision-makersLarge information-sufficiency gap between in-house and send-out segmentsLarge implementation-risk gap between in-house and send-out segmentsIndexed · blinded values
Heat Map · Barriers by Institution Segment
Barriers concentrate differently by segment: non-academic hospitals are gated by staffing and reimbursement, academic hospitals by capital competition.
Intensity of selected barriers across segment cuts (indexed within row to peak segment = 100). The heat map reveals which engagement obstacles dominate by institution type, system structure, and setting.
| Academic | Non-academic | IDN | Standalone | Rural | |
|---|---|---|---|---|---|
| Staffing and workforce gaps | 57 | 93 | 78 | 29 | 100 |
| Reimbursement uncertainty | 48 | 82 | 51 | 100 | 90 |
| Competing capital priorities | 100 | 58 | 91 | 55 | 64 |
| Lengthy approval processes | 100 | 70 | 95 | 55 | 75 |
| Lack of qualified staff (purchase barrier) | 60 | 87 | 76 | 65 | 100 |
Voice of Customer
How clinical lab buyers describe each phase of the journey.
Verbatims from AI-moderated interviews, selected to represent the range of triggers, evaluation experiences, financial gates, and stakeholder dynamics that define the clinical capital-instrument purchase journey.
Trigger · TAT Pressure
“The specific pain point was the prolonged turnaround times on send-out tests to reference labs. Once the clinical service line started losing patients on timing, the conversation about insourcing became unavoidable.”
— Laboratory Director, Mid-Sized Academic Hospital, Recent Purchaser
Financial Gate · ROI Justification
“It really boiled down to the return on investment, comparing the cost of sending the test out versus the potential net-neutral gain of adding the instrument. The numbers had to work before we could move.”
— Laboratory Director, Mid-Sized Academic Hospital, Recent Purchaser
Information Gap · Cross-Platform Comparison
“I wish there had been some head-to-head information comparing the leading instruments in the category. That kind of independent comparison is genuinely hard to find, and demos do not substitute for it.”
— Pathologist, Academic Medical Center, Recent Purchaser
Vendor Demo · Operational Reality
“Vendor demos can be loaded because they are usually set up in a way that makes the instrument run smoothly, and it is hard to get to the details that matter for our actual workflow.”
— Laboratory Manager, Community Hospital, Active Evaluator
Staffing Constraint · Expansion Barrier
“We would need to find, recruit, retain, and train staff in order to increase volume. The instrument is the smallest part of the conversation. The people are the constraint.”
— Laboratory Director, Mid-Tier Academic Hospital, Recent Purchaser
Implementation Surface · Hidden Costs
“Getting an analyzer is a huge purchase, and there are a lot of other things that come with it: the reagents, the kits, implementing the analyzer, the validation, making sure we have middleware that will communicate with it.”
— Hospital Administrator, Community Hospital, Active Evaluator
Site Visit · Trust Anchor
“The site visits, we have always found very useful. It is a chance to talk to existing customers, get their feedback in a setting where the vendor is not controlling the conversation.”
— Pathologist, Large-Tier Academic Hospital, Recent Purchaser
Champion Pathway · Patient Outcomes
“Medical specialists and ordering physicians are the ones working directly with the patients. They know why these would mean better outcomes, and they bring the clinical credibility the rest of the committee needs.”
— Laboratory Director, Integrated-System-Affiliated Academic Hospital, Recent Purchaser
Counter-intuitive
Clinical urgency does not move deals forward. Financial justification does, and a meaningful share of buying processes report no stakeholder pushback at all when the lab director builds pre-alignment first.
The prevailing assumption in clinical commercial strategy is that demonstrated clinical need closes the deal. The data shows otherwise. Turnaround-time pressure and patient demand are the dominant triggers, but financial justification is the single most cited catalyst that actually advances the process, well ahead of clinical need recognition. Cost is the dominant objection. Yet a meaningful share of buyers report no pushback at all when the lab director builds cross-stakeholder pre-alignment before formal committee review. The implication for commercial engagement is that the highest-leverage moment is not clinical-evidence delivery; it is supplying the lab director with the financial-justification artifacts and stakeholder-coalition tools that pre-empt CFO and committee objections before the proposal is filed.
Strategic Implications
Three commercial engagement moves from the research.
What the commercial team took into account-based engagement planning, grounded in the journey map, the segment cuts, and the stakeholder dynamics.
01
Engineer the financial justification artifact as a first-class commercial deliverable, sized to the lab director.
Financial justification advances a meaningful share of decisions. Cost objections drive the majority of pushback. The highest-leverage commercial asset is a lab-director-ready ROI model that translates send-out spend, in-house economics, reimbursement assumptions, and capital amortization into a cross-functional business case the CFO can sign. This is a working artifact that pre-empts the dominant objection.
02
Build a peer reference and site visit program as the centerpiece of Phase 2 engagement.
Peer recommendations are the #1 information source and peer site visits deliver the most trusted evaluation experience. Cross-region buyers value site visits even more strongly. The peer reference program should be treated as core commercial infrastructure, with reference accounts curated by tier, delivery model, and clinical application, and with site visit logistics handled by the commercial team rather than left to ad-hoc coordination.
03
Segment commercial engagement by testing delivery model: send-out labs require a distinct play from in-house labs.
Send-out labs face a different objection surface (majority cite implementation risk versus near-zero for in-house) and a categorical information deficit (near-zero report vendor information sufficiency versus a strong majority of in-house labs). The send-out conversion play needs implementation-risk-reduction tooling, validation data, and IVD-marked assay positioning, while the in-house expansion play needs capacity, automation, and competitive cross-platform comparison content.
Success criteria · 12 months
- Financial justification artifact deployed to every active opportunity within Phase 1 of the journey
- Peer reference network covering each tier, delivery model, and primary clinical application area
- Send-out conversion play documented with implementation-risk reduction collateral and IVD positioning
- Stakeholder coalition playbook for lab directors covering pathologist, specialist, and CFO pre-alignment
Risk register
| Reimbursement uncertainty | HIGH |
| Competing capital priorities | HIGH |
| Staffing constraints across every phase | HIGH |
| Information deficit for send-out segment | MED |
| Lengthy approval processes | MED |